MJA 217 9 7 Nov cover

Issues

Volume 217 Issue 9

7 November 2022

News

7 November 2022 Free

News briefs

New hope for pancreatic cancer patients Researchers from the Olivia Newton‐John Cancer Research Institute and the La Trobe University School of Cancer Medicine have found a novel drug target to potentially improve the treatment of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a low 5‐year survival rate and is associated with poor response to therapy. Elevated expression of the myeloid‐specific haematopoietic cell kinase (HCK) is observed in PDAC and correlates with reduced patient survival. To determine whether aberrant HCK signaling in myeloid cells is involved in PDAC growth and metastasis, the researchers established orthotopic and intrasplenic PDAC tumors in wild‐type and HCK knockout mice. Genetic ablation of HCK impaired PDAC growth and metastasis by inducing an immune‐stimulatory endotype in myeloid cells, which in turn reduced the desmoplastic microenvironment and enhanced cytotoxic effector cell infiltration. Consequently, genetic ablation or therapeutic inhibition of HCK minimised metastatic spread, enhanced the efficacy of chemotherapy, and overcame resistance to anti‐PD1, anti‐CTLA4, and stimulatory anti‐CD40 immunotherapy. The researchers argued their results provided a strong rationale for HCK to be developed as a therapeutic target to improve the response of PDAC to chemo‐ and immunotherapy. The study was published in Cell Reports. “This is important because most pancreatic cancer patients do not respond to existing anti‐cancer drugs, and the survival rate of pancreatic cancer has not improved over the past few decades. We hope to eventually translate these findings into the clinic and improve survival outcomes for pancreatic cancer patients,” lead author Dr Ashleigh Poh said. https://www.cell.com/cell‐reports/fulltext/S2211‐1247(22)01329‐8 Evaluating the worth of early ADHD diagnosis Research from the University of Sydney and Bond University examining quality of life in relation to attention deficit hyperactivity disorder (ADHD) diagnoses suggests a diagnosis in childhood is currently not associated with improved quality of life for Australian teens. The researchers called for a cautious approach to diagnosis by clinicians, particularly for children with mild or borderline hyperactive and inattentive behaviours. The researchers said they were pleased public discussion and new guidelines are creating increased dialogue about ADHD, but felt more research was needed to inform a robust evidence base for diagnosis. The study, which followed 746 children from ages 6–7years to 14–15years from 2006 to 2018, is published in JAMA Network Open. The study followed the children from diagnosis until they were teenagers and self‐reported their perceptions at 14 or 15years of age. The researchers found similar quality of life overall, health, happiness and peer trust. However, those with an ADHD diagnosis reported worse sense of school membership, academic self‐concept and self‐efficacy, more negative social behaviours, and were twice as likely to self‐harm. The researchers suggested that as the study shows youths could potentially be harmed by diagnosis, and interventions to support them may not yet be achieving the desired effects, a cautious clinical approach to ADHD diagnosis in children and adolescents is recommended. In particular, the researchers call for increased and targeted support — within and beyond the medical system — for girls, and for children with high levels of hyperactive and inattentive behaviours, irrespective of whether they are diagnosed. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797259

Perspectives

Environmental health 26 October 2022 Open Access

The 2022 report of the MJALancet Countdown on health and climate change: Australia unprepared and paying the price

Australia’s transition to renewables and zero carbon remains unacceptably slow

Paul J Beggs · Ying Zhang · Alice McGushin · Stefan Trueck · Martina K Linnenluecke · Hilary Bambrick · Anthony G Capon · Sotiris Vardoulakis · Donna Green · Arunima Malik · Ollie Jay · Maddie Heenan · Ivan C Hanigan · Sharon Friel · Mark Stevenson · Fay H Johnston · Celia McMichael · Fiona Charlson · Alistair J Woodward · Marina B Romanello

Medical education

Editorials

Environmental health 19 October 2022 Open Access

COP27 Climate Change Conference: urgent action needed for Africa and the world

Wealthy nations must step up support for Africa and vulnerable countries in addressing past, present and future impacts of climate change

Lukoye Atwoli · Gregory E Erhabor · Aiah A Gbakima · Abraham Haileamlak · Jean‐Marie Kayembe Ntumba · James Kigera · Laurie Laybourn‐Langton · Bob Mash · Joy Muhia · Fhumulani Mavis Mulaudzi · David Ofori‐Adjei · Friday Okonofua · Arash Rashidian · Maha El‐Adawy · Siaka Sidibé · Abdelmadjid Snouber · James Tumwine · Mohammad Sahar Yassien · Paul Yonga · Lilia Zakhama · Chris Zielinski

Research

Letter

Allergy 7 November 2022 Free

Integration with electronic medication management systems is non‐negotiable for a national allergy/ADR register

To the Editor: We read with interest the article by Drewett and colleagues,1 on anaphylaxis presentations to emergency departments in Victoria, and the linked editorial by Lucas and Vale,2 which proposes a comprehensive adverse drug reaction registry to improve patient safety and care. Re‐exposure of a patient to a medicine to which they have had a previously documented allergy or adverse drug reaction (ADR) is a preventable clinical incident. The Australian sentinel events list includes “medication error resulting in serious harm or death” to ensure public accountability and transparency and drive national improvements in patient safety.3 The availability of accurate and up to date allergy/ADR information for prescribers is vital to support the decision on appropriate treatment and to prescribe a medicine. It is also critical that health professionals who administer medicines and pharmacists who dispense medicines have access to accurate allergy/ADR information, as they provide redundancy within the medication management system to prevent unintentional re‐exposure. We recently undertook an audit to assess the accuracy of medication history documentation performed by pharmacists. Our methodology has been published elsewhere.4 As part of this work, we assessed the quality of pharmacist‐documented allergy/ADR information. Allergy/ADR documentation best practice suggests documentation of the medication name, reaction details and reaction date.5 New findings from our audit identified a total of 108 allergies/ADRs across 99 patients. Of the 52 patients with a previous history of allergy/ADR, only 31% (n = 16) had complete and correct allergy/ADR information documented. These results highlight that the current systems do not adequately support clinicians to provide safe and high quality care. Moreover, these systems risk patient harm through inadvertent re‐exposure to a medicine where there is a previously documented allergy/ADR, given that, at the point of prescribing, administration or dispensing, data are not available, disparate, incorrect or incomplete. We believe the national allergy/ADR registry proposed by Lucas and Vale2 should go one step further, and legislation should mandate interoperability between all electronic prescribing, administration and dispensing systems in Australia. A further challenge will be populating accurate historical allergy/ADR information into the registry. It would require high quality documentation to assist informed clinical decision making. An additional challenge is the complex, hybrid paper and electronic prescribing and documentation systems used across health care settings. Even though these may be challenges to overcome, there are potential opportunities through patient engagement, incentive schemes and machine learning. There needs to be a national consumer‐focused education campaign so the public can be active participants in their own care to support optimal medicine choice based on their allergy/ADR history. We believe a national allergy/ADR registry is of key importance to further enhance patient safety and will be a true system change to overcome the barriers we face in day‐to‐day clinical practice.

Martin L Canning · Andrew Munns · Bonnie Tai

Supplement

Next Issue Volume 217 Issue 10

View more
MJA 217 10 21 Nov cover
News 21 November 2022 Free

News briefs

Perspectives 7 November 2022 Open Access

Chlamydia prevention and management in Australia: reducing the burden of disease

Stephanie C Munari · Jane L Goller · Margaret E Hellard · Jane S Hocking

Perspectives 21 November 2022 Open Access

Strengthening the reporting of harms of all interventions in clinical trials

Christina Abdel Shaheed · Christopher G Maher · Ann‐Mason Furmage · Tammy Hoffmann · Andrew J McLachlan

Perspectives 31 October 2022 Open Access

Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective

Nadia N Khan · Harleen Basrai · Sue M Evans · Liane J Ioannou · Charles HC Pilgrim · John R Zalcberg · Gayle M Jones · Susan Hanson

Previous Issue Volume 217 Issue 8

View more
MJA 217 8 17 Oct cover
News 17 October 2022 Free

News briefs

Perspectives 19 September 2022 Open Access

Twenty‐one years at the Uniting Medically Supervised Injecting Centre, Sydney Australia: addressing the remaining questions

Carolyn A Day · Allison Salmon · Marianne Jauncey · Mark Bartlett · Amanda Roxburgh

Perspectives 12 September 2022 Open Access

Latest evidence casts further doubt on the effectiveness of headspace

Steve Kisely · Jeffrey CL Looi

Perspectives 3 October 2022 Open Access

Robotic surgery: getting the evidence right

Wei Shen Tan · Anthony Ta · John D Kelly

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.